Evidence map›Paper›PMID 39592322›Full record

ArticleClinical lymphoma, myeloma & leukemia2025

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase.

Fadi G Haddad, Koji Sasaki, Jayastu Senapati, Shimin Hu, Sara Dellasala, Ghayas C Issa, Elias Jabbour, Hagop Kantarjian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fadi G HaddadDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: fhaddad@mdanderson.org.
Koji SasakiDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Jayastu SenapatiDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Shimin HuHematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Sara DellasalaDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Ghayas C IssaDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Elias JabbourDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Hagop KantarjianDepartments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632
6 · The paper itself

Abstract

introductionThe discontinuation of third-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is not well understood. We aim to evaluate treatment-free remission in patients with CML-CP who discontinue ponatinib.

methodsWe retrospectively reviewed 361 patients who attempted TKI discontinuation between November 2005 and February 2024 and identified those receiving ponatinib at the time of discontinuation. Molecular relapse-free survival (MRFS) was calculated from the time of ponatinib discontinuation to the date of loss of major molecular response (MMR) or last follow-up.

resultsEleven patients discontinued ponatinib. Before ponatinib discontinuation, patients were on TKI therapy for a median of 146.6 months and on ponatinib for a median of 67.5 months. The median number of TKIs prior to starting ponatinib was 2 (range, 1-3). The median durations of sustained MR4 and MR4.5 before ponatinib discontinuation were 32.8 and 29.4 months, respectively. After a median follow-up of 60.3 months, the 60-month MRFS rate was 53%. Five patients lost MMR; their median MR4.5 duration was 5 months before ponatinib discontinuation.

conclusionPonatinib discontinuation is feasible in patients with CML-CP failing prior TKIs. Patients who achieve sustained MR4.5 for at least 2 years have the highest likelihood of remaining in treatment-free remission following ponatinib discontinuation.

Indexed as

ImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsPyridazinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeImidazolesponatinibProtein Kinase InhibitorsPyridazinesCessationIntoleranceResistanceTFRTyrosine kinase inhibitor

Identifiers

PMID39592322
PMCPMC11911093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.